The use of genetic sequencing in drug development is expanding and Life Technologies ($LIFE) is lining up its pieces to get more of that market with a manufacturing plant expansion in Scotland.
The company says that Scottish economic development agencies are providing some help so that it can invest $20 million in its operations in Inchinnan. The expansion will increase production of its GIBCO cell culture products.
The company said it expects the site up and running next year and actually shipping products in 2014. It will serve markets in Europe, the Middle East and Africa. There are currently 500 employees working at its facility at Inchinnan.
It didn't disclose the level of incentives provided by Scotland, but Life Technologies CEO Gregory Lucier said the company is "grateful for the support."
Life Technologies seems to be reminding potential customers it is in the game after all of the attention has been focused on competitor Illumina ($ILMN) and its back-and-forth battle with Roche ($RHHBY). The Swiss company last week gave up its $6.7 billion, $51-per-share bid for Illumina after its board repeatedly threw up roadblocks to the hostile takeover attempt.
- here's the PBR story
- check out Life Technologies' release
Roche's bid for Illumina may be kaput